Filing Details

Accession Number:
0001209191-24-001960
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-19 18:26:28
Reporting Period:
2024-01-18
Accepted Time:
2024-01-19 18:26:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1539029 Clearside Biomedical Inc. CLSD () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1020514 M George Lasezkay C/O Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta GA 30005
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-01-19 18,000 $1.27 466,577 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Acquisiton 2024-01-18 439,500 $0.00 439,500 $1.29
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
439,500 2034-01-18 No 4 A Direct
Footnotes
  1. The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations inconnection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded bya "sell to cover" transaction.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to$1.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth inthis footnote.
  3. One-fourth of the shares underlying this option vest on January 18, 2025 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.